GENEVA, Switzerland--(BUSINESS WIRE)--Sept. 6, 2005--SpinX Technologies, a privately held provider of innovative technology to perform biological assays, today announced that it has secured EUR 10 million (12.5 million USD) in a Series B financing. The round was led by Bio Fund Management, with equal participation from seed and Series A investor Index Ventures, as well as from Auriga Partners and DFJ ePlanet Ventures. The CERN Pension Fund also participated in the financing. The funds raised will support the further development and initial commercialization of SpinX's "programmable microfluidics" platform to perform biological assays.
